A method for producing recombinant adeno-associated virus (rAAV) vector particles at high recovery or high titer said method comprising the steps of: (a) harvesting cells and/or cell culture supernatant comprising rAAV vector particles; (b) optionally concentrating said cells and/or said cell culture supernatant harvested in step (a), optionally via tangential flow filtration, to produce a concentrated harvest; (c) lysing said harvest produced in step (a) or said concentrated harvest produced in step (b) optionally by microfluidization to produce a lysate; (d) filtering said lysate produced in step (c) to produce a clarified lysate; (e) subjecting said clarified lysate produced in step (d) to ion exchange column chromatography to produce a column eluate comprised of purified rAAV vector particles, and optionally concentrating said column eluate by tangential flow filtration to produce a concentrated column eluate; (f) mixing said column eluate or said concentrated column eluate produced in step (e) with cesium chloride to produce a mixture, and subjecting said mixture to gradient ultracentrifugation to substantially separate bona fide rAAV vector particles from empty capsid AAV particles and other AAV vector related impurities; (g) collecting said bona fide rAAV vector particles separated in step (f) and (g) formulating said collected bona fide rAAV vector particles in a buffer with a non-ionic surfactant; (h) subjecting said bona fide rAAV vector particles in step (g) to a buffer exchange by tangential flow filtration to produce an AAV vector formulation; and (i) filtering said AAV vector formulation produced in step (h) thereby producing a formulation of bona fide rAAV vector particles at high recovery or high titer. (a) harvesting cells and/or cell culture supernatant comprising rAAV vector particles; (b) optionally concentrating said cells and/or said cell culture supernatant harvested in step (a), optionally via tangential flow filtration, to produce a concentrated harvest; (c) lysing said harvest produced in step (a) or said concentrated harvest produced in step (b) optionally by microfluidization to produce a lysate; (d) filtering said lysate produced in step (c) to produce a clarified lysate; (e) subjecting said clarified lysate produced in step (d) to ion exchange column chromatography to produce a column eluate comprised of purified rAAV vector particles, and optionally concentrating said column eluate by tangential flow filtration to produce a concentrated column eluate; (f) mixing said column eluate or said concentrated column eluate produced in step (e) with cesium chloride to produce a mixture, and subjecting said mixture to gradient ultracentrifugation to substantially separate bona fide rAAV vector particles from empty capsid AAV particles and other AAV vector related impurities; (g) collecting said bona fide rAAV vector particles separated in step (f) and (g) formulating said collected bona fide rAAV vector particles in a buffer with a non-ionic surfactant; (h) subjecting said bona fide rAAV vector particles in step (g) to a buffer exchange by tangential flow filtration to produce an AAV vector formulation; and (i) filtering said AAV vector formulation produced in step (h) thereby producing a formulation of bona fide rAAV vector particles at high recovery or high titer.